- New analysis of the phase 2a clinical trial JANUS showed reduced atacicept immune complex levels in patients with IgA nephropathy (IgAN).
- Atacicept is the first therapeutic to demonstrate a reduction in all three first hits of IgAN pathogenesis – serum galactose-deficient IgA1 (Gd-IgA1), anti-Gd-IgA1, and now immune complex levels
- The final results of the Phase 2 clinical trial of MAU868 compared to placebo showed that MAU868 was well tolerated and demonstrated clinically meaningful BK antiviral activity over 36 weeks in renal transplant patients with BK viraemia
BRISBANE, Calif., November 05, 2022 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. VERA, a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients suffering from severe immunological disorders, today announced new clinical data from the company’s two product candidates, atacicept in immunoglobulin A nephropathy (IgAN) and MAU868 in kidney transplantation, were presented. These data were presented in poster and oral presentations at the 2022 American Society of Nephrology (ASN) Kidney Week Annual Meeting, held November 3-6, 2022 in Orlando, Florida.
The atacicept poster presentation included a new analysis of previously presented clinical data from the Phase 2a JANUS clinical trial evaluating atacicept in patients with IgAN, demonstrating reduced atacicept immune complex levels in patients with IgAN. Atacicept is the first therapeutic to provide a reduction in all of the first three hits of…
